Adding rolapitant improves prevention of chemo-induced nausea, vomiting
the ONA take:
Rolapitant in combination with a 5-HT3 receptor antagonist and dexamethasone is well-tolerated and demonstrates superiority over active control for the prevention of chemotherapy-induced nausea and vomiting (CINV) during the at-risk period following the administration of highly emetogenic cisplatin-based chemotherapy, a new study published online ahead of print in The Lancet Oncology has shown.
Two double-blind, active-controlled, phase 3 trials were conducted to assess rolapitant, a neurokinin-1 receptor antagonist, for the prevention of CINV in patients with cancer in the 120 hours after administration of cisplatin-based chemotherapy.
Patients were randomly assigned to receive either oral rolapitant 180 mg or placebo 1 to 2 hours before cisplatin in conjunction with granisetron and dexamethasone. Results showed that a significantly higher proportion of patients in the rolapitant arms achieved completes responses during the delayed phase than did patients who received placebo.
In regard to safety, no serious treatment-emergent adverse events were related to rolapitant treatment.
The findings suggest that adding rolapitant to granisetron and dexamethasone is superior to granisetron and dexamethasone alone for the prevention of CINV during the delayed phase after receiving cisplatin-based chemotherapy.
Rolapitant demonstrates superiority over active control for the prevention of chemotherapy-induced nausea and vomiting.
Sign Up for Free e-newsletters
- Scalp Cooling With Dignicap May Reduce Alopecia During Chemotherapy for Breast Cancer
- Evolution of HER2-Positive Breast Cancer: Yesterday, Today, and Tomorrow
- Dedicated End-of-Life Education Program Improves Nurses' Care, Patient and Family Satisfaction
- Reflexology, Aromatherapy May Reduce Pain, Anxiety of Brachytherapy for Cervical Cancer
- Oncology Extended Care Clinic Reduced Urgent Cancer-Related ED Visits
- Hair Dyes and Cancer Risk (Fact Sheet)
- Taste Changes After Hematopoietic Stem Cell Transplant Affect QOL in Blood Cancers
- Hope, Optimism Reduce Psychological Distress in Advanced Cancer
- Mitomycin Extravasation Protocol
- Accurate Understanding of Capacity May Improve Workflow, Efficiency in Infusion Suite
- Nursing Practice Change Improved Chemo Administration, But Old Habits Die Hard
- Simple Adjustment Key to Paclitaxel Infusion Protocol That Reduced Hypersensitivity Reactions
- Online Program Aims to Assist With Clinical Trial Enrollment for Hematologic Cancers
- Education May Better Equip Nurses to Hold End-of-Life Conversations in Advanced Cancer
- Skipping the SICU Post Head and Neck Cancer Surgery May Improve Outcomes
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|